Title Category Credit Event datesort ascending Cost
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
12/09/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
11/19/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Adaptive Protocols and Practical Strategies for the Use of Novel Anticoagulation Reversal Agents
  • Cardiology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
11/10/2020 $0.00 This interprofessional, community Grand Rounds initiative is targeted to addressing the professional practice of physicians, pharmacists, nurse practitioners, physician assistants, nurses, and other healthcare professionals, who manage patients who are taking anticoagulation therapy, and who may require reversal agents for direct oral anticoagulants to address acute bleeding complications.
Traversing New Terrains In CLL: The Emerging Role Of BTK Inhibitors In The Treatment Landscape
  • Oncology
  • ANCC
  • Participation
10/28/2020 $0.00 The objective of this activity is to provide evidence-based information on the latest developments for the use of Bruton’s tyrosine kinase (BTK) inhibitors in patients with chronic lymphocytic leukemia (CLL). Given the demonstrated clinical benefit of BTKi therapy and its advantages over chemotherapy, it is essential for patients that the adoption of BTKi therapy continues to accelerate. Optimizing patient adherence to oral BTKis is vital to achieving efficacy and improving clinical outcomes.
Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine
  • Oncology
  • ANCC
  • Participation
10/20/2020 $0.00 Attendees will gain an appreciation of the latest advances in non-small cell lung cancer (NSCLC), including the nurse’s role in comprehensive biomarker testing strategies and biomarker-driven treatment approaches. Expert faculty will reflect on the lung cancer tumor board, with emphasis on the appropriate selection of targeted therapy based on patient- and biomarker-specific factors in oncogenic driver mutations.
Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine
  • Oncology
  • ANCC
  • Participation
10/15/2020 $0.00 Attendees will gain an appreciation of the latest advances in non-small cell lung cancer (NSCLC), including the nurse’s role in comprehensive biomarker testing strategies and biomarker-driven treatment approaches. Expert faculty will reflect on the lung cancer tumor board, with emphasis on the appropriate selection of targeted therapy based on patient- and biomarker-specific factors in oncogenic driver mutations.
Adaptive Protocols and Practical Strategies for the Use of Novel Anticoagulation Reversal Agents
  • Cardiology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
10/14/2020 $0.00 This interprofessional, community Grand Rounds initiative is targeted to addressing the professional practice of physicians, pharmacists, nurse practitioners, physician assistants, nurses, and other healthcare professionals, who manage patients who are taking anticoagulation therapy, and who may require reversal agents for direct oral anticoagulants to address acute bleeding complications.
Putting NSCLC to the Test: Oncology Nurse Perspectives in the Era of Precision Medicine
  • Oncology
  • ANCC
  • Participation
10/13/2020 $0.00 Attendees will gain an appreciation of the latest advances in non-small cell lung cancer (NSCLC), including the nurse’s role in comprehensive biomarker testing strategies and biomarker-driven treatment approaches. Expert faculty will reflect on the lung cancer tumor board, with emphasis on the appropriate selection of targeted therapy based on patient- and biomarker-specific factors in oncogenic driver mutations.
Stepping Beyond the Status Quo in Heart Failure: The Revolutionary Role of SGLT2 Inhibition
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • ICPE
  • Participation
10/13/2020 $0.00 This Grand Rounds initiative is targeted to cardiologists, endocrinologists, primary care physicians, pharmacists, nurses, nurse practitioners, and physician assistants. Designed to foster meaningful interprofessional and interdisciplinary collaboration, this accredited activity will explore the evolution of SGLT2 inhibition in the era of cardiovascular outcomes trials (CVOTs), as well as evaluate foundational mechanisms linking type 2 diabetes (T2D) to heart failure (HF).
Immune-Related Adverse Events with Cancer Immunotherapy: Case-Based Challenges for the Oncology Nurse
  • Oncology
  • ANCC
  • Participation
10/07/2020 $0.00 Early identification of irAEs and initiation of systemic immunosuppression can improve outcomes without compromising the efficacy of immune checkpoint inhibition. As front-line caregivers, oncology nurses are optimally positioned to quickly identify such adverse events and employ appropropriate management strategies.

Pages